The predictors of biochemical recurrence and metastasis following radical perineal prostatectomy in clinically localized prostate cancer

Korean Journal of Urology

Volumn 46, Issue 11, 2005, Pages 1161-1167

  Hong, Jeong Hee ^a   Lee, Hyun Moo ^a   Choi, Han Yong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Prostate cancer; Prostatectomy; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOLUMINESCENCE; DISEASE COURSE; EARLY DIAGNOSIS; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL APPROACH; SURGICAL TECHNIQUE;

EID: 28644451659     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7
2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-8
3. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71
4. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507
5. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 1997;49(3A Suppl):23-30
6. Partin AW, Pearson JD, Landis PK, Carter HB, Pound CR, Clemens JQ, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-59
7. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158:1441-5
8. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406
9. Rogers CG, Khan MA, Craig Miller M, Veltri RW, Partin AW. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 2004;101:2549-56
10. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-40
11. Kim WJ CJ, Hong JH, Kim CS, Jung SI, Yoon DK. Epidemiologic study for urologic cancer in Korea (1998-2002). Korean J Urol 2004;45:1081-8
12. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 2001;165:1146-51
13. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61:365-9
14. Kupelian P, Katcher J, Levin H, Zippe C, Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48:249-60
15. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81
16. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000;164:101-5